BP and Nova Chemicals to Create One of Europe’s Largest Polystyrene Manufacturers by Forming a Joint Venture

BP and NOVA Chemicals Corporation. announced today that they have reached an agreement in principle to combine their European interests in Styrene Polymers to create one of the largest polystyrene and expandable polystyrene manufacturers and marketers in Europe. BP and NOVA Chemicals will each have a 50 per cent stake.

The proposed joint venture, which is subject to a number of regulatory and other consents, is expected to commence during early 2005, and be headquartered in Fribourg, Switzerland.

These products will be produced at seven manufacturing locations across Europe: NOVA Chemicals’ existing sites at Carrington, UK; Breda, Holland; Ribecourt, France; and Berre, France and the current BP sites at Marl, Germany; Wingles, France; and Trelleborg, Sweden.

Ralph Alexander, CEO of BP’s Olefins and Derivatives business said: “Our combined customer base will see better product and geographic coverage, and greater scale leading to improved service. The key benefits of the proposed deal are product and technology leverage, rationalisation of commercial operations and production optimisation across the asset base.”

NOVA Chemicals will retain its styrenics business across the Americas whilst BP’s Olefins and Derivatives business will retain its styrene monomer production facilities and interest in the polystyrene production facilities in the SECCO joint venture in China and will continue to offer licensing packages to other parties.

For more information on polystyrene, click here.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.